Nevertheless, most RCTs and nonrandomized interventional trials in patients with MM since the development of CXCR4is for HSPC mobilization have reported that currently available regimens frequently yield suboptimal CD34+ numbers despite multiple injections and multiple days of apheresis12,13,39,40. This evidence concerns the gene CD34 and Miyoshi myopathy.